2026 Antoni Ribas: Medicine Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Medicine	167	575	525	334	300	898	179491

Antoni Ribas publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Antoni Ribas sits on this spectrum.

101 publications 1,796+

This scientist: 898 publications — 91st percentile

91% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Antoni Ribas D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Antoni Ribas sits on this spectrum.

70 D-Index 217+

This scientist: 167 D-Index — 97th percentile

97% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

2020 - Member of the National Academy of Medicine (NAM)

Overview

Antoni Ribas is affiliated with the University of California, Los Angeles in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a strong focus on Oncology, Molecular Biology, and Immunology. Their work contributes extensively to Cancer Research and Radiology, Nuclear Medicine, and Imaging.

The main topics of their research include Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Melanoma and MAPK Pathways, Immunotherapy and Immune Responses, Cutaneous Melanoma Detection and Management, Immune Cell Function and Interaction, and Cancer Genomics and Diagnostics.

Among their frequent co-authors are Katie M. Campbell, Georgina V. Long, Caroline Robert, Egmidio Medina, and Paolo A. Ascierto. Over time, their research has been published repeatedly in several venues, notably Cancer Research, Journal of Clinical Oncology, Cancer Discovery, bioRxiv (Cold Spring Harbor Laboratory), and Clinical Cancer Research.

Recent publications include:

Multiple early factors anticipate post-acute COVID-19 sequelae, 2022, Cell
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma, 2023, New England Journal of Medicine
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction, 2020, Cell
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134, 2022, Journal of Clinical Oncology
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma, 2020, Cancer Cell

Their research contributions reflect a strong engagement with cancer immunotherapy, especially regarding melanoma treatment and immune response mechanisms.

Antoni Ribas is a member of the National Academy of Medicine (NAM), an award received in 2020.

Best Publications

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Paul B. Chapman;Axel Hauschild;Caroline Robert;John B. Haanen

9013
Citations
PD-1 blockade induces responses by inhibiting adaptive immune resistance

Paul C. Tumeh;Christina L. Harview;Jennifer H. Yearley;I. Peter Shintaku

6998
Citations
Cancer immunotherapy using checkpoint blockade

Antoni Ribas;Jedd D. Wolchok;Jedd D. Wolchok

6368
Citations
Pembrolizumab versus Ipilimumab in Advanced Melanoma

Caroline Robert;Caroline Robert;Caroline Robert;Jacob Schachter;Georgina V. Long;Ana Arance

5794
Citations
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Alexandra Snyder;Vladimir Makarov;Taha Merghoub;Jianda Yuan

4702
Citations
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Padmanee Sharma;Siwen Hu-Lieskovan;Jennifer A. Wargo;Antoni Ribas

4321
Citations
Inhibition of mutated, activated BRAF in metastatic melanoma.

Keith T. Flaherty;Igor Puzanov;Kevin B. Kim;Antoni Ribas

4208
Citations
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Omid Hamid;Caroline Robert;Adil Daud;F. Stephen Hodi

4127
Citations
IFN- γ –related mRNA profile predicts clinical response to PD-1 blockade

Mark Ayers;Jared Lunceford;Michael Nebozhyn;Erin Murphy

3793
Citations
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

Jesse M. Zaretsky;Angel Garcia-Diaz;Daniel S. Shin;Helena Escuin-Ordinas

3292
Citations
Genomic and transcriptomic features of response to anti-pd-1 therapy in metastatic melanoma

Willy Hugo;Jesse M. Zaretsky;Lu Sun;Chunying Song

3025
Citations
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

Mark E. Davis;Jonathan E Zuckerman;Chung Hang J Choi;David Seligson

2934
Citations
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

Caroline Robert;Boguslawa Karaszewska;Jacob Schachter;Piotr Rutkowski

2792
Citations
Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

Jeffrey A. Sosman;Kevin B. Kim;Lynn Schuchter;Rene Gonzalez

2560
Citations
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Ramin Nazarian;Hubing Shi;Qi Wang;Xiangju Kong

2540
Citations
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

James Larkin;Paolo A. Ascierto;Brigitte Dréno;Victoria Atkinson

2277
Citations
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial

Caroline Robert;Antoni Ribas;Jedd D. Wolchok;F. Stephen Hodi

2103
Citations
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF -mutant melanoma

Gideon Bollag;Peter Hirth;James Tsai;Jiazhong Zhang

2018
Citations
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

G.V. Long;D. Stroyakovskiy;H. Gogas;E. Levchenko

1955
Citations
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

Ravid Straussman;Teppei Morikawa;Kevin Shee;Michal Barzily-Rokni

1935
Citations

Frequent Co-Authors

Georgina V. Long University of Sydney

Caroline Robert University of Paris-Saclay

Grant A. McArthur Peter MacCallum Cancer Centre

Keith T. Flaherty Harvard University

James S. Economou University of California, Los Angeles

Jeffrey A. Sosman Northwestern University

Richard F. Kefford Macquarie University

Paolo A. Ascierto National Institutes of Health

Adil Daud University of California, San Francisco

Omid Hamid Cedars-Sinai Medical Center

External Links

Personal website of Antoni Ribas

If you think any of the details on this page are incorrect, let us know.

Related Online Degrees & Career Pathways

For those considering a career in Medicine or healthcare, there are several flexible online degree options to support your journey. Nurses looking to specialize can explore psychiatric np programs, which prepare you for advanced practice in mental health and are often offered with fast-track online formats.

If you're interested in the administrative side of healthcare, pursuing healthcare administration degrees opens doors to management roles in hospitals, clinics, and public health organizations. Many institutions now offer affordable online options, making it easier to balance studies with professional commitments.

For those aiming higher, a masters in healthcare administration cost can be a concern, but numerous universities provide budget-friendly online programs. Similarly, registered nurses looking to advance their careers can consider the cheapest online bsn to dnp programs to gain the highest level of clinical nursing education and leadership skills.

These online degree pathways offer flexibility, affordability, and specialized training to help you progress in the ever-evolving healthcare sector.